A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 420 participants.
Also called NCT02298192
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 420 participants
- Sponsor
- Registry
-
NCT02298192 -
2012-004625-25
-
- Main results
- Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Austria, Bulgaria, Canada, Czechia, Hungary, Russia, Serbia, Slovakia
- Registry status
- Completed
Technical summary
Registry record NCT02298192. Randomized; no masking; primary purpose treatment. Start 2014-11-21 (actual); primary completion 2015-12-23 (actual). Results posted on 2017-05-23.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms
- Acronym
- DUAL™ VI
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- insulin degludec/liraglutide
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct02298192- Content hash
2f265dc51f674d204d5ae529656538bedb3557e7bd618cc9d22f0806c3a4d0ac